Exelixis reported revenue of approximately $628.7 million for the second quarter of 2026, missing Wall Street consensus estimates. While adjusted earnings of $0.91 per share actually exceeded analyst projections, the market focused on the top-line deficit and the company's decision to lower its full-year 2026 revenue outlook. Leadership at Exelixis cited a slower-than-anticipated performance in its neuroendocrine-tumor business as the primary factor behind the reduced forecast.
In section Releases
Exelixis Faces Shareholder Investigation Following Revenue Miss
A 7.9% slide in share price has prompted Levi & Korsinsky to launch an investigation into Exelixis, Inc. following second-quarter results that fell short of analyst expectations. The law firm is currently reviewing potential securities law violations linked to the company’s revenue shortfall and its subsequent downward guidance revision.
Levi & Korsinsky, a firm specializing in shareholder class actions, is now examining whether Exelixis provided materially misleading information to investors. The investigation specifically targets the period surrounding the second-quarter report and the revised financial guidance. Investors who incurred losses following these disclosures are being encouraged to submit their trade records for a contingency-based evaluation, regardless of whether they currently hold the stock or have already sold their positions.
Comments (0)
No comments yet. Be the first!